Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Journal of the American Heart Association · 06.05.2025 · 14 (9)
DOI: 10.1161/jaha.124.039446 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of the American Heart Association, erschienen am 06.05.2025. Verfasst von Yiwen Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health Peking Union Medical College Hospital, Peking Union Medical College,…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Pulmonary Embolism, Venous Thromboembolism, Venous Thrombosis. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
Limited data exist on the association of glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) with the risk of venous thromboembolism. This meta‐analysis aimed to investigate the association between GLP‐1RAs and the risk of venous thromboembolism including deep vein thrombosis (DVT) and pulmonary embolism. Methods and Results A systematic search of PubMed, Web of Science, EMBASE, and Cochrane library was conducted from inception until July 3, 2024, to identify randomized controlled trials comparing GLP‐1RAs with placebo or other anti‐iabetic drugs, with reported data on DVT and pulmonary embolism. The primary outcome was venous thromboembolism, and secondary outcomes included DVT and pulmonary embolism. Pooled odds ratios (ORs) were calculated using fixed‐effects models with Mantel–Haenszel method and treatment arm continuity correction for zero‐event trials. A total of 39 randomized controlled trials involving 70 499 participants were included. A nonsignificant upward trend in the risk of venous thromboembolism was observed among participants using GLP‐1RAs (OR, 1.19 [95% CI, 0.94–1.50]). GLP‐1RAs were significantly associated with an increased risk of DVT (OR, 1.64 [95% CI, 1.14–2.36]); risk difference 25 (5–52) more events per 10 000 person‐years). Subgroup analyses revealed that increased risk of DVT was particularly prominent in randomized controlled trials with treatment duration >1.5 years (OR, 2.32 [95% CI, 1.49–3.60]) and in cardiovascular outcome trials (OR, 2.18 [95% CI, 1.36–3.49]). No significant association was observed between GLP‐1RAs and risk of pulmonary embolism.
Conclusions
GLP‐1RAs might increase the risk of DVT, especially for long‐term use of GLP‐1RAs. Clinicians should be aware of this potential risk when prescribing GLP‐1RAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences Beijing China.
ORCID-Profile: Yiwen Liu, Shumeng Han, Huabing Zhang, Yuxiu Li
Zitieren
APA
Liu, Y., He, L., Han, S., Ping, F., Li, W., Xu, L., Zhang, H., & Li, Y. (2025). Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 14(9). https://doi.org/10.1161/jaha.124.039446
Vancouver
Liu Y, He L, Han S, Ping F, Li W, Xu L, et al. Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Journal of the American Heart Association. 2025;14(9). doi:10.1161/jaha.124.039446
BibTeX
@article{Liu2025,
author = {Liu, Yiwen and He, Liyun and Han, Shumeng and Ping, Fan and Li, Wei and Xu, Lingling and Zhang, Huabing and Li, Yuxiu},
title = {Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {9},
doi = {10.1161/jaha.124.039446}
}
EUVIMED